1. |
Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer, 1989, 63(5): 908-911.
|
2. |
Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep, 2015, 5: 7748.
|
3. |
Choi JB, Lee WK, Lee SG, et al. Long-term oncologic outcomes of papillary thyroid microcarcinoma according to the presence of clinically apparent lymph node metastasis: a large retrospective analysis of 5 348 patients. Cancer Manag Res, 2018, 10: 2883-2891.
|
4. |
Kim JY, Jung EJ, Park T, et al. Impact of tumor size on subclinical central lymph node metastasis in papillary thyroid microcarcinoma depends on age. World J Surg Oncol, 2015, 13: 88.
|
5. |
Liu LS, Liang J, Li JH, et al. The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Otorhinolaryngol, 2017, 274(3): 1327-1338.
|
6. |
Moo TA, McGill J, Allendorf J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg, 2010, 34(6): 1187-1191.
|
7. |
Chang YW, Kim HS, Kim HY, et al. Should central lymph node dissection be considered for all papillary thyroid microcarcinoma? Asian J Surg, 2016, 39(4): 197-201.
|
8. |
李茵, 杨中元, 李秋梨, 等. 分化型甲状腺癌区域淋巴结清扫策略及争议. 中国实用外科杂志, 2015, 35(6): 642-646.
|
9. |
He Q, Zhuang D, Zheng L, et al. The surgical management of papillary thyroid microcarcinoma: a 162-month single-center experience of 273 cases. Am Surg, 2012, 78(11): 1215-1218.
|
10. |
Roh JL, Kim JM, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol, 2008, 15(9): 2482-2486.
|
11. |
Heid IM, Jackson AU, Randall JC, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet, 2010, 42(11): 949-960.
|
12. |
李晓京, 杨乐, 马斌林. 1988 例甲状腺微小乳头状癌颈部中央区淋巴结转移危险因素分析. 临床耳鼻咽喉头颈外科杂志, 2017, 31(1): 52-57.
|
13. |
王猛, 魏玺, 郑向前, 等. 甲状腺微小乳头状癌临床病理特征与中央区淋巴结转移的相关性探讨. 天津医科大学学报, 2018, 24(2): 138-141.
|
14. |
刘鹏杰, 唐铭, 邓智勇, 等. BRAFV600E 基因突变与甲状腺微小乳头状癌淋巴结转移的相关性研究. 现代肿瘤医学, 2019, 27(4): 552-556.
|
15. |
禹乐, 朱启淦, 温路生, 等. BRAFV600E 基因突变与甲状腺微小乳头状癌临床病理特征的相关性. 山西医科大学学报, 2019, 50(9): 1214-1217.
|
16. |
Pitoia F, Miyauchi A. 2015 American thyroid association guidelines for thyroid nodules and differentiated thyroid cancer and their implementation in various care settings. Thyroid, 2016, 26(2): 319-321.
|
17. |
Takami H, Ito Y, Noguchi H, et al. Treatment of thyroid tumor: Japanese clinical guidelines. Tokyo: Springer, 2013: 111-113.
|
18. |
中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016 版). 中国肿瘤临床, 2016, 43(10): 405-411.
|
19. |
Lee HS, Roh JL, Gong G, et al. Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg, 2015, 39(8): 1943-1950.
|
20. |
郑珏如, 戴磊, 吴贤江, 等. 甲状腺患侧叶联合峡部切除术治疗甲状腺微小乳头状癌的近远期疗效. 中华全科医学, 2019, 17(4): 568-570, 656.
|
21. |
张伟伟, 李向农. 三种术式在甲状腺微小乳头状癌外科治疗中的应用效果比较. 中华普外科手术学杂志(电子版), 2017, 11(5): 397-399.
|
22. |
伊丹丹, 黄韬, 宋鹏, 等. 甲状腺微小乳头状癌手术方式对肿瘤复发影响的 meta 分析. 东南大学学报(医学版), 2017, 36(1): 48-52.
|
23. |
韩茜, 张广, 孙辉. 超声引导下热消融治疗甲状腺微小乳头状癌研究进展. 中国普外基础与临床杂志, 2017, 24(9): 1156-1160.
|
24. |
李建如, 罗渝昆. 超声引导下射频消融治疗甲状腺微小乳头状癌的初步研究. 中国人民解放军医学院, 2016.
|
25. |
Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg, 2010, 34(1): 28-35.
|
26. |
Noguchi S, Yamashita H, Uchino S, et al. Papillary microcarcinoma. World J Surg, 2008, 32(5): 747-753.
|